🔔 Approval Alert
Lupin receives FDA approval for Emtricitabine and Tenofovir Alafenamide Tablets, eligible for 180 days of shared generic exclusivity.
Lupin Ltd Analyst Rating
based on 36 analysts
51.43%
Buy
28.57%
Hold
20.00%
Sell
Based on 36 analysts offering long term price targets for Lupin Ltd. An average target of ₹2218.36
Source: S&P Global Market Intelligence
Lupin Ltd Share analysis
Lupin Ltd price forecast by 36 analysts
Upside of5.68%
High
₹2750
Target
₹2218.36
Low
₹1519
Lupin Ltd target price ₹2218.36, a slight upside of 5.68% compared to current price of ₹2162.85. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin Ltd revenue growth forecast
Expected growth rate Q1, FY2026:25.24%
Forecast
Actual
Including amortisation and stock based compensations
Lupin Ltd EPS growth forecast
EPS estimate Q1, FY2026:95.76%
Forecast
Actual
Source: S&P Global Market Intelligence
Lupin Ltd Performance
Day's Low
Day's High
₹2,079.2Day's Price Range₹2,166.952 Week's Low
52 Week's High
₹1,200.1552-Week Price Range₹2,312
| Returns % | |
| 1 Month Return | + 2.99 % |
| 3 Month Return | -3.35 % |
| 1 Year Return | + 65.26 % |
| Market Stats | |
| Previous Close | ₹2,099.10 |
| Open | ₹2,090.00 |
| Volume | 18.64L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹95,760.43Cr |
Lupin Ltd Key Statistics
| P/E Ratio | 36.42 |
| PEG Ratio | 1.28 |
| Market Cap | ₹95,760.43 Cr |
| P/B Ratio | 3.58 |
| EPS | 42.47 |
| Dividend Yield | 0.49 |
| Sector | Pharmaceuticals |
| ROE | 11.92 |
Lupin Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹95,760.43 Cr | 34.48% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹14,100.35 Cr | -2.4% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹73,098.77 Cr | 33.75% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹98,565.65 Cr | 54.86% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹59,732.90 Cr | 22.46% | 0.53 | NA | NA |
Lupin Ltd Mutual Fund Holdings
About Lupin Ltd
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Share Price: ₹2162.85 per share as on 19 Dec, 2024 04:01 PM
Market Capitalisation: ₹95,760.43Cr as of today
Revenue: ₹5,497.01Cr as on September 2024 (Q3 24)
Net Profit: ₹859.48Cr as on September 2024 (Q3 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
What's happening today
Today's Timeline - 19 Dec
08:21 AM
-Lupin receives FDA approval for Emtricitabine and Tenofovir Alafenamide Tablets, a generic version of Gilead's Descovy.
08:33 AM
-Lupin's FDA approval allows marketing of a generic equivalent of Descovy, with estimated annual sales of USD 3,556 million.
11:33 AM
-Shares of Lupin rise 1% after FDA approval announcement for Emtricitabine and Tenofovir Alafenamide Tablets.
Today's Timeline - 19 Dec
01:28 PM
-Lupin's stock trades 2.57% higher following FDA approval for its ANDA for Emtricitabine and Tenofovir Alafenamide Tablets.
Key events for Lupin Ltd
Lupin Secures FDA Approval for Generic HIV Tablets - 18 Dec, 2024
Lupin Ltd announced FDA approval for its generic version of Descovy tablets, allowing it to market emtricitabine and tenofovir alafenamide. The company is among the first to gain this approval, securing 180 days of shared exclusivity in the US market.Lupin Expands Market Share and Digital Health Services - 17 Dec, 2024
Lupin Ltd is gaining market share in Mirabegron with a new product launch and has partnered with Medicover Hospitals to enhance cardiac post-operative care through its digital platform, Lyfe.Lupin Strengthens Diabetes Portfolio with Trademark Acquisition - 13 Dec, 2024
Lupin Ltd has acquired trademarks for three anti-diabetes medications from Boehringer Ingelheim, aiming to expand its diabetes treatment offerings in India. The acquisition supports Lupin's commitment to providing effective and affordable healthcare solutions.Lupin Shares Rise Amid Positive Trading Activity - 11 Dec, 2024
Lupin Ltd. shares increased by 0.63% to Rs 2148.00, with an intraday high of Rs 2153.00. The company reported consolidated sales of Rs 5715.02 crore for Q2 FY2024, reflecting a 12.52% year-over-year growth. Net profit surged 74.19% compared to the same quarter last year.LIC Reduces Stake in Lupin Ltd Significantly - 10 Dec, 2024
Life Insurance Corporation has divested 2.027% equity in Lupin Ltd, reducing its shareholding to 2.542%. The reduction occurred through open market transactions between July 30 and December 6, 2024.LIC Reduces Stake in Lupin Ltd Significantly - 09 Dec, 2024
Life Insurance Corporation has reduced its shareholding in Lupin Ltd by nearly half, divesting 2.027% equity, bringing its stake down to 2.542%. The sale occurred between September 30 and December 6.Lupin's R&D Facility Achieves LEED Platinum Certification - 06 Dec, 2024
Lupin Limited announced that its R&D facility at Lupin Research Park in Pune has received LEED Platinum Certification, recognizing its commitment to sustainability and environmental practices.Lupin Shares Rise Amid Positive Trading Activity - 03 Dec, 2024
Lupin Ltd. shares increased by 0.7% to Rs 2084.00, with an intraday high of Rs 2091.00. The company reported consolidated sales of Rs 5715.02 crore for Q3 FY2024, reflecting a 12.52% year-over-year growth. Net profit surged 74.19% compared to the same quarter last year.Lupin Receives Tentative FDA Approval for Diabetes Drug - 02 Dec, 2024
Lupin Limited confirmed it received tentative US FDA approval for its generic version of Janumet® Tablets, used for treating Type-2 Diabetes. The company noted that this approval does not have a material financial impact at present.Lupin Gains USFDA Approval for Diabetes Drug - 29 Nov, 2024
Lupin Limited announced receiving tentative approval from the USFDA for its generic Sitagliptin and Metformin Hydrochloride Tablets, boosting investor confidence and share prices.Lupin Enhances Humrahi Program for Diabetes and Heart Health - 28 Nov, 2024
Lupin Limited has relaunched its Humrahi diabetes support program, now incorporating heart health management. This initiative aims to provide comprehensive care for patients, addressing both diabetes and cardiovascular risks, thereby improving health outcomes and promoting adherence to therapy.Lupin Faces Recall and Share Price Decline - 26 Nov, 2024
Lupin Ltd is recalling over 600,000 bottles of a blood pressure medication due to manufacturing issues. The stock fell 2.71% amid bearish signals from MACD.Lupin Faces Recall but Continues Stock Gains - 25 Nov, 2024
Lupin Ltd is recalling over 600,000 bottles of a hypertension drug due to manufacturing issues. Despite this, the stock has gained 1.94% today and 69.6% over the past year.Lupin Stock Faces Continued Decline - 21 Nov, 2024
Lupin Ltd has been experiencing a steady decline in stock price since the beginning of November 2024. Last week, it fell below a critical support level, indicating potential for further price drops.Lupin Secures Approvals for Key Generic Drugs - 20 Nov, 2024
Lupin Limited announced USFDA approvals for its generic formulations of Adderall XR for ADHD and Bumetanide Injection for edema treatment, indicating strong market opportunities.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 359.43 Cr → 852.63 Cr (in ₹), with an average increase of 30.6% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 19.32% to 21.50% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 4.99K Cr → 5.71K Cr (in ₹), with an average increase of 6.4% per quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, LUPIN stock has moved up by 33.5%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.23% to 16.89% in Sep 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 6.92% to 6.44% in Sep 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 46.98% to 46.96% in Sep 2024 quarter
Lupin Ltd Financials
Index Inclusions
Lupin Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.96% | ||
| Foreign Institutions | 21.5% | 11.30 | |
| Mutual Funds | 16.89% | 4.06 | |
| Retail Investors | 6.44% | ||
| Others | 8.21% |
Lupin Ltd Key Indicators
Lupin Ltd Valuation
Lupin Ltd in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (36.42x)
December 18, 2024
Industry (55.74x)
December 18, 2024
Highest (517.33x)
December 2, 2022
Lupin Ltd Earnings and Dividends
Lupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.57%.
Read More about Dividends
Lupin Ltd Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Lupin Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Lupin Ltd shares.
Lupin Ltd (LUPIN) share price today is ₹2162.85
Lupin Ltd is listed on NSE
Lupin Ltd is listed on BSE
- Today’s highest price of Lupin Ltd is ₹2166.9.
- Today’s lowest price of Lupin Ltd is ₹2079.2.
PE Ratio of Lupin Ltd is 36.42
PE ratio = Lupin Ltd Market price per share / Lupin Ltd Earnings per share
Today’s traded volume of Lupin Ltd(LUPIN) is 18.64L.
Today’s market capitalisation of Lupin Ltd(LUPIN) is ₹95760.43Cr.
| Lupin Ltd(LUPIN | Price |
|---|---|
52 Week High | ₹2312 |
52 Week Low | ₹1200.15 |
Lupin Ltd(LUPIN) share price is ₹2162.85. It is down -6.45% from its 52 Week High price of ₹2312
Lupin Ltd(LUPIN) share price is ₹2162.85. It is up 80.21% from its 52 Week Low price of ₹1200.15
| Lupin Ltd(LUPIN | Returns |
|---|---|
1 Day Returns | 63.75% |
1 Month Returns | 2.99% |
3 Month Returns | -3.35% |
1 Year Returns | 65.26% |